• Ceribell won a CMS New Technology Add-on Payment for up to USD 2,171 per eligible Medicare inpatient case using its Delirium Monitor System.
• Payment add-on under Medicare’s IPPS takes effect Oct. 1, 2026, improving hospital reimbursement economics for the new monitoring service.
• Decision follows FDA 510(k) clearance in December 2025 for the delirium device, positioning it as the only FDA-cleared aid for delirium screening.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ceribell Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802205) on August 03, 2026, and is solely responsible for the information contained therein.